JP5613900B2 - Aqueous photocatalytic composition and anticancer agent decomposition method using the composition - Google Patents
Aqueous photocatalytic composition and anticancer agent decomposition method using the composition Download PDFInfo
- Publication number
- JP5613900B2 JP5613900B2 JP2010240664A JP2010240664A JP5613900B2 JP 5613900 B2 JP5613900 B2 JP 5613900B2 JP 2010240664 A JP2010240664 A JP 2010240664A JP 2010240664 A JP2010240664 A JP 2010240664A JP 5613900 B2 JP5613900 B2 JP 5613900B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- photocatalyst
- aqueous
- photocatalytic
- titanium dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 55
- 239000002246 antineoplastic agent Substances 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 16
- 230000001699 photocatalysis Effects 0.000 title claims description 16
- 238000000354 decomposition reaction Methods 0.000 title claims description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 65
- 239000011941 photocatalyst Substances 0.000 claims description 32
- 239000004408 titanium dioxide Substances 0.000 claims description 28
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 6
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 239000003945 anionic surfactant Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- -1 alkylbenzene sulfonates Chemical class 0.000 description 19
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 18
- 229960004397 cyclophosphamide Drugs 0.000 description 17
- 229910001220 stainless steel Inorganic materials 0.000 description 12
- 239000010935 stainless steel Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000004034 viscosity adjusting agent Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003871 sulfonates Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 125000005037 alkyl phenyl group Chemical group 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000004711 α-olefin Substances 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- MCYYJHPHBOPLMH-UHFFFAOYSA-L disodium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane;hydrate Chemical compound O.[Na+].[Na+].[O-]S([O-])(=O)=S MCYYJHPHBOPLMH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940127075 other antimetabolite Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- FURYAADUZGZUGQ-UHFFFAOYSA-N phenoxybenzene;sulfuric acid Chemical class OS(O)(=O)=O.C=1C=CC=CC=1OC1=CC=CC=C1 FURYAADUZGZUGQ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Landscapes
- Catalysts (AREA)
Description
本発明は、光触媒水性組成物及び該組成物を用いた抗がん剤分解法に関し、詳細には、二酸化チタンを含み、分解対象物上に噴霧して使用することを特徴とする光触媒水性組成物及び該組成物を用いた、医療用安全キャビネット内に付着した抗がん剤の分解方法に関する。 The present invention relates to an aqueous photocatalyst composition and a method for decomposing an anticancer agent using the composition, and in particular, it contains titanium dioxide and is used by spraying onto an object to be decomposed. The present invention relates to a method for decomposing an anticancer agent attached to a medical safety cabinet using the composition and the composition.
薬剤師等の抗がん剤を取り扱う医療従事者の抗がん剤被爆が問題となっている。抗がん剤被爆は、微量ではあるが長期にわたるため、流産などの生殖毒性や発癌のリスク増加に繋がると報告されている(S.G. Selevan, M.L. Lindbohm, R.W. Hornung, K. Hemminki, A study of occupational exposure to antineoplastic drugs and fetal loss in nurses, N. Engl. J. Med, 313, 1173-1178 (1985))。 The exposure of anti-cancer drugs to medical workers who handle anti-cancer drugs such as pharmacists is a problem. Exposure to anticancer drugs has been reported to be associated with increased reproductive toxicity such as miscarriage and an increased risk of carcinogenesis due to the long-term exposure (SG Selevan, ML Lindbohm, RW Hornung, K. Hemminki, A study of occupational exposure to antineoplastic drugs and fetal loss in nurses, N. Engl. J. Med, 313, 1173-1178 (1985)).
抗がん剤の取り扱いに関し、日本病院薬剤師会監修、「注射薬・抗がん剤無菌調製ガイドライン」では、24時間運転の安全キャビネット内で行うこと、該安全キャビネット内を定期的に清掃すること等が推奨されている。該清掃方法としては、抗がん剤をアルカリ等で失活させた後にアルコール清拭すること、また、定期的に0.3M水酸化ナトリウム溶液で清拭し、薬剤種に応じて2%次亜塩素酸ナトリウム水、1%チオ硫酸ナトリウム水などを併用すること等が推奨されている。 Regarding the handling of anticancer drugs, according to the “Guidelines for Aseptic Preparation of Injections and Anticancer Drugs” supervised by the Japan Hospital Pharmacists Association, perform in a 24-hour safety cabinet and regularly clean the safety cabinet. Etc. are recommended. As the cleaning method, the anticancer agent is deactivated with an alkali or the like and then wiped with alcohol, or regularly wiped with a 0.3 M sodium hydroxide solution, depending on the type of drug. It is recommended to use sodium chlorite water, 1% sodium thiosulfate water, etc. together.
しかし、これら分解液の使用は、使用薬剤毎に使い分ける点や人体に刺激性がある点、使用後に水拭き除去しなくてはならない点で煩雑である。さらに、発がん性が報告されているシクロホスファミドなど一部の抗がん剤は、分解液として推奨されている0.3M水酸化ナトリウム水溶液中で、わずか28.5%しか分解されず、安全キャビネット内の3回の拭き取りによっても除去率は70%台と完全な拭き取り除去は困難であったと報告されている(望月千枝, 藤川郁世, 丁元鎮, 吉田仁, 抗がん剤調製用安全キャビネットの清拭用洗浄液の比較, 日本病院薬剤師会雑誌, 44, 601-604 (2008))。 However, the use of these decomposition solutions is complicated in that they are used for each drug used, are irritating to the human body, and must be wiped off after use. In addition, some anticancer agents such as cyclophosphamide, which have been reported to be carcinogenic, are only 28.5% decomposed in a 0.3M aqueous sodium hydroxide solution recommended as a decomposition solution, and are not contained in the safety cabinet. It was reported that the removal rate of 70% was difficult even after three times of wiping (Chie Mochizuki, Sayo Fujikawa, Zhenmotojin, Hitoshi Yoshida, safety cabinet for anticancer drug preparation) Comparison of cleaning liquids for wiping, Journal of Japanese Hospital Pharmacists Association, 44, 601-604 (2008)).
一方、二酸化チタンの光触媒活性を利用して、シクロホスファミド及び5−フロロウラシルを、渦巻き状のホウケイ酸ガラス上にコーティングされた二酸化チタンの薄膜上で無害な無機物に分解することが提案されている(非特許文献1)。また、医療施設の抗菌用途等に利用される、二酸化チタンゾルを含む水性組成物も提案されている(特許文献1)。 On the other hand, using photocatalytic activity of titanium dioxide, it has been proposed to decompose cyclophosphamide and 5-fluorouracil into harmless inorganic substances on a thin film of titanium dioxide coated on spiral borosilicate glass. (Non-Patent Document 1). Moreover, the aqueous composition containing the titanium dioxide sol utilized for the antimicrobial use etc. of a medical facility is also proposed (patent document 1).
二酸化チタン光触媒を使用する際には、図2に示すように、該二酸化チタンを何らかの基材上に固定化し、分解対象物(図中×印で表したもの)が該基材上に在る状態で分解するのが通常である。上記特許文献1においても、洗浄した塩化ビニル板等の基板に水性組成物を筆で塗布した後、常温で二日間乾燥させて塗膜状に固定化している(特許文献1、実施例)。これは、触媒自体は反応において変化を受けないので、繰り返し触媒活性を利用するために、固定化して使用するのが経済的にも理に適った方法だからである。 When using the titanium dioxide photocatalyst, as shown in FIG. 2, the titanium dioxide is fixed on some base material, and an object to be decomposed (denoted by x in the figure) is present on the base material. It is normal to decompose in the state. Also in the said patent document 1, after apply | coating an aqueous composition to board | substrates, such as the wash | cleaned vinyl chloride board, with a brush, it is dried at normal temperature for two days, and is fixed to the film form (patent document 1, an Example). This is because the catalyst itself is not subject to change in the reaction, and therefore it is economically reasonable to use it by immobilizing it in order to utilize the catalytic activity repeatedly.
しかし、既に使用され、抗がん剤で汚染された安全キャビネットは、安全性を考慮すると、一旦完全に清掃した上で二酸化チタンを固定化しなければならず、大変な労力、時間、及びコストがかかる。 However, safety cabinets already used and contaminated with anti-cancer drugs must be thoroughly cleaned and then fixed with titanium dioxide for safety reasons. Take it.
そこで、本発明は既に使用され、抗がん剤で汚染されている安全キャビネットに於いても、手軽に、抗がん剤を除去することができる方法を提供することを目的とする。 Therefore, an object of the present invention is to provide a method capable of easily removing an anticancer agent even in a safety cabinet that is already used and contaminated with the anticancer agent.
即ち、本発明は、
0.1〜1.0重量%の光触媒活性な二酸化チタン粒子、及び
0.3〜0.5重量%の界面活性剤、
を含み、分解対象物上に噴霧して使用されることを特徴とする光触媒水性組成物、
である。
That is, the present invention
0.1 to 1.0% by weight of photocatalytically active titanium dioxide particles, and 0.3 to 0.5% by weight of a surfactant,
An aqueous photocatalyst composition characterized by being used by spraying on an object to be decomposed,
It is.
図1に示すように、本発明では、安全キャビネット内に上記光触媒水性組成物を噴霧した後、光を照射して分解する。触媒が分解対象物の上に在る点、及び、触媒を設備に固定化せずに一時的に施与する点で、常識を覆すものである。所定の組成の光触媒水性組成物を霧状にしてキャビネットのステンレス面に施与することによって、膜状にして使用するのよりも優れた分解効率を達成できる。また、触媒を繰り返し使用できないコスト面でのデメリットも、該光触媒水性組成物がバインダー等の製膜用成分を含まず、施工費用がかからないことから、問題無い範囲に収めることができる。本発明の光触媒水性組成物であれば、既に抗がん剤で汚染された安全キャビネットに対しても手軽に使用することができる。 As shown in FIG. 1, in this invention, after spraying the said photocatalyst aqueous composition in a safety cabinet, it decomposes | disassembles by irradiating light. The point that the catalyst is present on the object to be decomposed and that the catalyst is temporarily applied without being fixed to the equipment are overturned. By applying a photocatalytic aqueous composition having a predetermined composition in the form of a mist to the stainless steel surface of the cabinet, it is possible to achieve a decomposition efficiency superior to that of using it in the form of a film. In addition, the cost disadvantage that the catalyst cannot be used repeatedly can be within the range of no problem since the aqueous photocatalyst composition does not contain a film-forming component such as a binder and does not require construction costs. If it is the photocatalyst aqueous composition of this invention, it can be easily used also with respect to the safety cabinet already contaminated with the anticancer agent.
最初に、本発明の光触媒水性組成物(以下、「光触媒組成物」という場合がある)について説明した後、該組成物を用いる分解方法を説明する。 First, after describing the aqueous photocatalyst composition of the present invention (hereinafter sometimes referred to as “photocatalyst composition”), a decomposition method using the composition will be described.
<二酸化チタン>
本発明の光触媒組成物において、二酸化チタンは光触媒活性を有するものであれば特に限定されず、アナターゼ型、ブルッカイト型、可視光反応型光触媒酸化チタンのいずれであってもよく、これらの混合物であってもよい。高い触媒活性を示す点で、ブルッカイト型がより好ましい。斯かるブルッカイト型二酸化チタンとしては、例えば、ナノチタニア(登録商標、昭和タイタニウム(株)製)等が挙げられる。
<Titanium dioxide>
In the photocatalytic composition of the present invention, titanium dioxide is not particularly limited as long as it has photocatalytic activity, and may be any of anatase type, brookite type, visible light reaction type photocatalytic titanium oxide, or a mixture thereof. May be. The brookite type is more preferable in view of high catalytic activity. Examples of such brookite type titanium dioxide include nano titania (registered trademark, manufactured by Showa Titanium Co., Ltd.).
該二酸化チタンの、動的光散乱法法で測定される粒径は、5nm〜150nmであることが好ましく、より好ましくは10nm〜100nmである。 The particle size of the titanium dioxide measured by the dynamic light scattering method is preferably 5 nm to 150 nm, more preferably 10 nm to 100 nm.
光触媒組成物中の二酸化チタンの含有量は、該組成物総重量に対して0.05〜1重量%、好ましくは0.1〜0.5重量%、より好ましくは0.1〜0.3重量%である。該含有量が前記下限値未満では、十分な触媒効果が得られず、一方、前記上限値を超えては、組成物中での二酸化チタンの分散安定性が悪くなる傾向がある。 The content of titanium dioxide in the photocatalyst composition is 0.05 to 1% by weight, preferably 0.1 to 0.5% by weight, more preferably 0.1 to 0.3% by weight based on the total weight of the composition. % By weight. If the content is less than the lower limit value, a sufficient catalytic effect cannot be obtained. On the other hand, if the content exceeds the upper limit value, the dispersion stability of titanium dioxide in the composition tends to deteriorate.
<界面活性剤>
界面活性剤としては、アニオン性、カチオン性、ノニオン性、及びベタイン界面活性剤を利用することができる。アニオン系界面活性剤としては、アルキルベンゼンスルホン酸塩、アルキルナフタレンスルホン酸塩、アルキルスルホン酸塩、α-オレフィンスルホン酸塩等のスルホン酸系界面活性剤;アルキル硫酸塩、ポリオキシエチレンアルキルエーテル硫酸塩、ポリオキシエチレンアルキルフェニールエーテル硫酸塩、ポリオキシエチレンスチレン化フェニールエーテル硫酸塩等の硫酸塩系界面活性剤;エーテルカルボン酸等のカルボン酸系界面活性剤;アルキルリン酸塩、ポリオキシエチレンアルキルエーテルリン酸塩等のリン酸エステル系界面活性剤が挙げられる。
<Surfactant>
As the surfactant, anionic, cationic, nonionic, and betaine surfactants can be used. Anionic surfactants include sulfonic acid surfactants such as alkylbenzene sulfonates, alkylnaphthalene sulfonates, alkyl sulfonates, α-olefin sulfonates; alkyl sulfates, polyoxyethylene alkyl ether sulfates , Sulfate surfactants such as polyoxyethylene alkyl phenyl ether sulfates, polyoxyethylene styrenated phenyl ether sulfates; carboxylic acid surfactants such as ether carboxylic acids; alkyl phosphates, polyoxyethylene alkyl ethers Examples thereof include phosphate ester-based surfactants such as phosphates.
カチオン系界面活性剤としては第1級〜第3級アルキルアミン塩;テトラアルキルアンモニウム塩、トリアルキルベンジルアンモニウム塩等の第4級アンモニウム塩;アルキルピリジウム塩、アルキルイミダゾリウム塩などを挙げることができる。 Examples of the cationic surfactant include primary to tertiary alkylamine salts; quaternary ammonium salts such as tetraalkylammonium salts and trialkylbenzylammonium salts; alkylpyridium salts and alkylimidazolium salts. it can.
ノニオン系界面活性剤としては、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンアルキルフェニールエーテル等のポリオキシアルキレン系界面活性剤;多価アルコール脂肪酸部分エステル、ポリオキシエチレン脂肪酸エステル、ポリグリセリン脂肪酸エステル、トリエタノールアミン脂肪酸部分エステル等の脂肪酸エステルを挙げることができる。 Nonionic surfactants include polyoxyalkylene surfactants such as polyoxyethylene alkyl ether and polyoxyethylene alkyl phenyl ether; polyhydric alcohol fatty acid partial ester, polyoxyethylene fatty acid ester, polyglycerin fatty acid ester, triethanol Examples include fatty acid esters such as amine fatty acid partial esters.
ベタイン系界面活性剤としては、N−トリアルキル−N−カルボキシメチルアンモニウムベタイン等のカルボキシベタイン、N−トリアルキル−N−スルフォアルキレンアンモニウムベタイン等のスルフォベタインが挙げられる。 Examples of the betaine surfactant include carboxybetaines such as N-trialkyl-N-carboxymethylammonium betaine and sulfobetaines such as N-trialkyl-N-sulfoalkylene ammonium betaine.
これらのうち、好ましくはアニオン性界面活性剤、より好ましくはアルキルベンゼンスルホン酸塩、アルキルナフタレンスルホン酸塩、アルキルスルホン酸塩、α-オレフィンスルホン酸塩等のスルホン酸系界面活性剤が使用される。 Of these, preferably used are anionic surfactants, more preferably sulfonic acid surfactants such as alkylbenzene sulfonates, alkylnaphthalene sulfonates, alkyl sulfonates, and α-olefin sulfonates.
光触媒組成物中の界面活性剤の含有量は、該組成物総重量に対して0.1〜3.0重量%、好ましくは0.3〜0.5重量%である。含有量が前記下限値未満では、十分な濡れ性改良効果が得られず、前記上限値を超えても、量に比例した二酸化チタンの濡れ性の向上は得られない。 The content of the surfactant in the photocatalyst composition is 0.1 to 3.0% by weight, preferably 0.3 to 0.5% by weight, based on the total weight of the composition. If the content is less than the lower limit, a sufficient wettability improving effect cannot be obtained, and even if the content exceeds the upper limit, the improvement of the wettability of titanium dioxide in proportion to the amount cannot be obtained.
<水>
光触媒組成物に使用する水は、二酸化チタンの触媒活性を失活させるナトリウム等の不純物が入っていなければよく、蒸留水、イオン交換水、精製水、超純水等のいずれであってよい。好ましくは、精製水が使用される。
<Water>
The water used in the photocatalyst composition may be any of distilled water, ion-exchanged water, purified water, ultrapure water, etc., as long as impurities such as sodium deactivating the catalytic activity of titanium dioxide are not contained. Preferably, purified water is used.
<任意成分>
上記各成分に加えて、本発明の光触媒組成物は、バインダ、水と相溶性である有機溶媒、及び粘度調整剤等を含むことができる。バインダとしてはアクリル系樹脂、例えば、共重合アクリル樹脂エマルジョン(固形分50%、水系)が挙げられる。該バインダを入れることによって、噴霧・乾燥後の、二酸化チタン微粉末の飛散が抑制され、安全性及び触媒活性を向上することができる。該バインダの量は、組成物総重量に対して、固形分で、0.001〜0.1重量%、好ましくは0.01〜0.05重量%、最も好ましくは0.02〜0.03重量%である。
<Optional component>
In addition to the above components, the photocatalyst composition of the present invention can contain a binder, an organic solvent compatible with water, a viscosity modifier, and the like. Examples of the binder include an acrylic resin, for example, a copolymerized acrylic resin emulsion (solid content 50%, aqueous). By adding the binder, scattering of the titanium dioxide fine powder after spraying and drying can be suppressed, and safety and catalytic activity can be improved. The amount of the binder is 0.001 to 0.1% by weight, preferably 0.01 to 0.05% by weight, most preferably 0.02 to 0.03% by solid content, based on the total weight of the composition. % By weight.
水と相溶性である有機溶媒としては、例えば、炭素数1〜6のアルコール、即ち、メタノール、エタノール、n−プロパノール、イソプロパノール、n−ブタノール、sec−ブタノール、t−ブタノール、ペンタノール等の一価アルコール類;エチレングリコール等の二価アルコール類等が挙げられる。該アルコールの含有量は、組成物総重量に対して1〜10重量%、好ましくは3〜7重量%である。 Examples of the organic solvent compatible with water include alcohols having 1 to 6 carbon atoms, that is, methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, t-butanol, pentanol and the like. And dihydric alcohols such as ethylene glycol. The content of the alcohol is 1 to 10% by weight, preferably 3 to 7% by weight, based on the total weight of the composition.
粘度調整剤としては、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ポリアクリル酸ソーダ、ポリアクリルアミド、ポリビニルピロリドン、ポリビニルアルコール、キサンタンガム等が挙げられる。好ましくは、ポリアクリル酸系粘度調整剤、例えば、ポリアクリル酸ソーダが使用され、分子量300万〜500 万のポリアクリル酸ソーダがより好ましい。光触媒組成物中の粘度調整剤の含有量は、光媒組成物のJIS−Z8803粘度測定方法で測定される粘度が2〜5mPa・sである量、好ましくは3〜4mPa・sとなる量である。アクリル酸系粘度調整剤を用いる場合には、該組成物総重量に対して0.1〜1重量%、好ましくは0.4〜0.8重量%である。 Examples of the viscosity modifier include carboxymethyl cellulose, hydroxyethyl cellulose, polyacrylic acid soda, polyacrylamide, polyvinyl pyrrolidone, polyvinyl alcohol, xanthan gum and the like. Preferably, a polyacrylic acid-based viscosity modifier, for example, sodium polyacrylate is used, and sodium polyacrylate having a molecular weight of 3 million to 5 million is more preferable. The content of the viscosity modifier in the photocatalyst composition is such that the viscosity measured by the JIS-Z8803 viscosity measurement method of the photomedium composition is 2 to 5 mPa · s, preferably 3 to 4 mPa · s. is there. When an acrylic acid viscosity modifier is used, it is 0.1 to 1% by weight, preferably 0.4 to 0.8% by weight, based on the total weight of the composition.
本発明の光触媒組成物は、上記各成分及び、所望により任意成分、をミキサー等の公知の攪拌手段を用いて混合することによって作ることができる。 The photocatalyst composition of the present invention can be prepared by mixing the above-mentioned components and, if desired, optional components using a known stirring means such as a mixer.
斯くして得られる光触媒組成物の使用方法は以下のとおりである。先ず、光触媒組成物を噴霧用容器に収納する。該噴霧用容器は、光触媒組成物を細かい霧状にして噴霧することができれば、どのようなタイプのものであってもよい。例えば、加圧式ハンドスプレー、電機式スプレー、エアスプレー等を使用することができる。 The method of using the photocatalyst composition thus obtained is as follows. First, the photocatalyst composition is stored in a spray container. The spray container may be of any type as long as the photocatalyst composition can be sprayed in a fine mist. For example, a pressurized hand spray, an electric spray, an air spray or the like can be used.
次いで、抗がん剤等を取り扱う医療用安全キャビネットの内壁に、光触媒組成物を万遍なく噴霧する。噴霧量は、二酸化チタン濃度、分解対象物等に依存して適宜調整することが好ましいが、約100〜150mL/m2であれば、平均的な安全キャビネットの内壁及び作業面を万遍無く濡らすことが可能である。一般に、キャビネットはステンレス製であるが、本発明の光触媒組成物の液滴は、弾かれずにステンレス表面を濡らすことができ、液滴となって落下することも無い。 Next, the photocatalyst composition is uniformly sprayed on the inner wall of a medical safety cabinet that handles anticancer agents and the like. The spray amount is preferably adjusted as appropriate depending on the titanium dioxide concentration, decomposition target, etc., but if it is about 100 to 150 mL / m 2 , the inner wall and work surface of the average safety cabinet will be uniformly wetted. It is possible. In general, although the cabinet is made of stainless steel, the droplets of the photocatalyst composition of the present invention can wet the stainless steel surface without being repelled, and do not fall as droplets.
噴霧後、30〜120分程度かけて、自然乾燥させる。乾燥後のステンレス面上には、二酸化チタン粒子が残留して、表面が白く見える。該二酸化チタン粒子は、強制的に擦ったりしない限り、粉が舞ったり、剥離されることはない。 After spraying, it is naturally dried over 30 to 120 minutes. On the stainless steel surface after drying, titanium dioxide particles remain and the surface looks white. As long as the titanium dioxide particles are not rubbed forcibly, they do not flutter or peel off.
次いで、二酸化チタンが光触媒活性を示す光を照射する。照射光源としては、例えば、315〜380nmの紫外線を出すブラックライト蛍光灯等を使用することができる。安全キャビネット内に装着されている紫外線灯を、ブラックライト蛍光灯に付け替えてもよい。照射時間は、光の強度及びキャビネットの汚染度にも依存して適宜調整することが好ましいが、照射強度が約0.2mW/cm2の強度の場合、約10〜15時間程度の照射で、良好な結果が得られた。 Next, the titanium dioxide is irradiated with light showing photocatalytic activity. As the irradiation light source, for example, a black light fluorescent lamp that emits ultraviolet rays of 315 to 380 nm can be used. The ultraviolet lamp mounted in the safety cabinet may be replaced with a black light fluorescent lamp. The irradiation time is preferably adjusted appropriately depending on the intensity of light and the degree of contamination of the cabinet, but when the irradiation intensity is about 0.2 mW / cm 2 , the irradiation is good for about 10 to 15 hours. Results were obtained.
本発明において、分解対象とする抗がん剤は特に限定されず、二酸化チタンの酸化作用によって分解される可能性があるものであればいずれの抗がん剤であってもよい。例えば5−フロロウラシル、メソトレキセート、シタラビン、ゲムシタビン、フルダラビン、ペメトレキセド、ネララビン、エノシタビン等の代謝拮抗剤、シクロホスファミド、ブスルファン、ダカルバジン、ニムスチン、ラニムスチン、イホスファミド、メルファラン、アクチノマイシンD、テモゾロミド等のアルキル化剤、シスプラチン、カルボプラチン、オキサリプラチン、ネダプラチン等のプラチナ剤、イリノテカン、ノギテカン、エトポシド等のトポイソメラーゼ阻害剤、パクリタキセル、ドセタキセル、ビンクリスチン、ブンブラスチン、ビンデシン、ビノレルビン等の微小管重合阻害剤、ドキソルビシンおよびそのリポソーム製剤、アクラルビシン、イダルビシン、ピラルビシン、ダウノマイシン、エピルビシン、ミトキサントロン、アムルビシン、ゲムツズマブオゾガマイシン等の抗がん抗生物質、抗体製剤、その他ペントスタチン、三酸化ヒ素、ブレオマイシン、マイトマイシン、クラドリビン、アスパラギナーゼなどの抗癌剤が挙げられる。 In the present invention, the anticancer agent to be decomposed is not particularly limited, and any anticancer agent may be used as long as it can be decomposed by the oxidizing action of titanium dioxide. For example, 5-fluorouracil, methotrexate, cytarabine, gemcitabine, fludarabine, pemetrexed, nelarabine, eninotabine and other antimetabolites, cyclophosphamide, busulfan, dacarbazine, nimustine, ranimustine, ifosfamide, melphalan, actinomycin D, temozolomide, etc. Alkylating agents, platinum agents such as cisplatin, carboplatin, oxaliplatin, nedaplatin, topoisomerase inhibitors such as irinotecan, nogitecan, etoposide, microtubule polymerization inhibitors such as paclitaxel, docetaxel, vincristine, bunblastine, vindesine, vinorelbine, doxorubicin and the like Liposome preparation, aclarubicin, idarubicin, pirarubicin, daunomycin, epirubicin, mitoxant Examples include anticancer antibiotics such as Ron, amrubicin and gemtuzumab ozogamicin, antibody preparations, and other anticancer agents such as pentostatin, arsenic trioxide, bleomycin, mitomycin, cladribine and asparaginase.
光照射後は、アルコール等で拭き取ってもよいし、抗がん剤の完全な分解を期するために、水酸化ナトリウム等を用いる拭き取り清掃を行ってもよい。冒頭で述べたように、従来の拭き取りを3回行なっても約70%程度しか除去されないシクロホスファミドの場合、以下の実施例で示すように、本発明の光触媒組成物の噴霧だけでも約60%程度分解することができるので、拭き取りを組みわせれば、約90%近く(88=60+40×0.7)分解することができる。或いは、毎日の作業終了後に本発明の光触媒組成物を噴霧して、夜中光照射を行い、何日かそれを繰り返した後に、まとめて拭き取りを行なってもよい。 After light irradiation, it may be wiped off with alcohol or the like, or may be wiped and cleaned using sodium hydroxide or the like to ensure complete decomposition of the anticancer agent. As described at the beginning, in the case of cyclophosphamide, which is removed only about 70% even if the conventional wiping is performed three times, as shown in the following examples, spraying of the photocatalyst composition of the present invention alone is about Since it can be decomposed by about 60%, it can be decomposed by about 90% (88 = 60 + 40 × 0.7) when wiping is combined. Alternatively, the photocatalyst composition of the present invention may be sprayed after completion of daily work, light irradiation is performed in the night, and after several days, the wiping may be performed collectively.
以下、本発明を実施例により説明するが、本発明はこれらに限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention, this invention is not limited to these.
ブルッカイト型二酸化チタンゾル(ナノチタニア、昭和タイタニウム(株)製)3.0w/v%、スルホン酸塩型アニオン界面活性剤(ノプコウェット、サンノプコ(株)製)0.5w/v%、共重合アクリル樹脂エマルジョン(パンテックス、固形分50%、伸葉(株)製)0.05w/v%、及び、蒸留水(残分)を混合して、光触媒二酸化チタン濃度0.1w/v%の組成物を調製した。 Brookite type titanium dioxide sol (Nano Titania, Showa Titanium Co., Ltd.) 3.0 w / v%, sulfonate type anionic surfactant (Nopco Wet, San Nopco Co., Ltd.) 0.5 w / v%, copolymer acrylic resin A composition having a photocatalytic titanium dioxide concentration of 0.1 w / v% by mixing an emulsion (PANTEX, solid content 50%, manufactured by Shinba Co., Ltd.) 0.05 w / v% and distilled water (residue). Was prepared.
光触媒二酸化チタン濃度を0.3w/v%としたことを除き、実施例1と同様にして光触媒濃度0.3w/v%の組成物を調製した。 A composition having a photocatalyst concentration of 0.3 w / v% was prepared in the same manner as in Example 1 except that the photocatalytic titanium dioxide concentration was 0.3 w / v%.
<比較例>
比較用に、昭和電工(株)製、ナノチタニア(商標)ゾルに付着剤としてジルコニアバインダーを配合したものを、10cm×10cmステンレス(SUS304)面に、厚み約0.2ミクロンとなるように塗布した後、120℃で焼き付け固着させて光触媒薄膜を得た。
<Comparative example>
For comparison, a nanotitania (trademark) sol manufactured by Showa Denko Co., Ltd., which was blended with a zirconia binder as an adhesive, was applied to a 10 cm × 10 cm stainless steel (SUS304) surface to a thickness of about 0.2 microns. Thereafter, it was baked and fixed at 120 ° C. to obtain a photocatalyst thin film.
[光触媒性能の評価]
安全キャビネットに使用されているものと同材質のステンレス板(SUS304;10cm×10cm)を、安全キャビネット内の作業平面上に配置した。該ステンレス板に、生理食塩水で調製したシクロホスファミド水溶液(注射用エンドキサン100(塩野義製薬(株))を、シクロホスファミドとして1mgおよび4mgとなるよう滴下した。該水溶液は界面活性剤を含まずステンレス面上で弾かれるため、それぞれ10および20mg/mLに調製したシクロホスファミド水溶液を1μLあるいは2μLずつピペットを用いて均一になるように100個の滴下スポットとした。滴下した溶液が乾燥後、実施例1又は2の組成物をハンドスプレー先端より20cm離れた場所から150mL/m2の容量で噴霧した。
[Evaluation of photocatalytic performance]
A stainless steel plate (SUS304; 10 cm × 10 cm) made of the same material as that used in the safety cabinet was placed on the work plane in the safety cabinet. Cyclophosphamide aqueous solution (endoxan 100 for injection (Shionogi Pharmaceutical Co., Ltd.) for injection) prepared with physiological saline was added dropwise to the stainless steel plate to give 1 mg and 4 mg as cyclophosphamide. In order to be repelled on the stainless steel surface without containing any agent, 100 μl or 2 μl of cyclophosphamide aqueous solution prepared to 10 and 20 mg / mL, respectively, was added dropwise using a pipette. After the solution was dried, the composition of Example 1 or 2 was sprayed at a volume of 150 mL / m 2 from a location 20 cm away from the hand spray tip.
噴霧した光触媒水性組成物が乾燥した後、全幅1.3mの安全キャビネット内部に装着されている紫外線灯をブラックライト(東芝FL20SBLB)に付け替え、作業平面に配置した試験ステンレス板に波長350nmの近紫外線を約0.2mW/cm2の強度で12時間照射した。 After the sprayed photocatalytic aqueous composition is dried, the UV light mounted inside the safety cabinet with a total width of 1.3 m is replaced with a black light (Toshiba FL20SBLB), and near ultraviolet light with a wavelength of 350 nm is placed on a test stainless steel plate placed on the work plane. Was irradiated at an intensity of about 0.2 mW / cm 2 for 12 hours.
近紫外線照射後、10mLの蒸留水と綿棒を用いて試験ステンレス板から滴下スポットを拭き取り、蒸留水で抽出後、得られた回収液を0.45μmのフィルターで濾過して、高速液体クロマトグラフ(HPLC)分析に供した。HPLC分析条件は後述する。対照群は、滴下したシクロホスファミド水溶液が乾燥後、光触媒水性組成物を噴霧せず同様に回収した。 After irradiation with near-ultraviolet light, wipe the drop spot from the test stainless steel plate using 10 mL distilled water and a cotton swab, extract with distilled water, filter the collected liquid with a 0.45 μm filter, and perform high-performance liquid chromatography (HPLC ) Used for analysis. The HPLC analysis conditions will be described later. In the control group, after the dripped cyclophosphamide aqueous solution was dried, the photocatalyst aqueous composition was recovered in the same manner without spraying.
比較例で調製した光触媒薄膜上にも、実施例と同様に、シクロホスファミドを1mg滴下し、近紫外線照射後、拭き取り回収を行った。対照群は、コーティング用光触媒を塗布していないステンレス板にシクロホスファミド水溶液を滴下し、乾燥後スプレー法と同様に回収した。 Similarly to the example, 1 mg of cyclophosphamide was dropped on the photocatalyst thin film prepared in the comparative example, and after irradiating near ultraviolet rays, the wipe was collected. In the control group, a cyclophosphamide aqueous solution was dropped onto a stainless steel plate not coated with a photocatalyst for coating, and after drying, collected in the same manner as the spray method.
上記一連の試験は、n=2又は3にて行い、シクロホスファミドの気化を防ぐため20℃に設定した室温で行った。 The above series of tests was performed at n = 2 or 3, and was performed at room temperature set to 20 ° C. to prevent vaporization of cyclophosphamide.
<シクロホスファミドの測定方法>
シクロホスファミドの定量は、HPLC法によっておこなった。測定条件は以下のとおりである。40℃に維持した分析カラム(関東化学;RP-8 、内径4.6mm×長さ250mm、粒子径5μm)に移動相として水:アセトニトリル = 75 : 25を流速 l.0 mL / minにて流した。オートサンプラーを用いて各サンプルを20μL注入し(n=3)、195 nmの波長にて検出した。定量限界は、0.3μg/mL、拭き取り量に換算すると300μg/m2であった。
<Method of measuring cyclophosphamide>
Cyclophosphamide was quantified by HPLC. The measurement conditions are as follows. Water: acetonitrile = 75: 25 was flowed as a mobile phase to an analytical column (Kanto Chemical; RP-8, inner diameter 4.6 mm × length 250 mm, particle diameter 5 μm) maintained at 40 ° C. at a flow rate of 1.0 mL / min. . 20 μL of each sample was injected using an autosampler (n = 3) and detected at a wavelength of 195 nm. The limit of quantification was 0.3 μg / mL, and 300 μg / m 2 when converted to the amount of wiping.
HPLCの定量結果を用い、対照群に対する試験群のシクロホスファミド回収量から分解率を算出した。結果を表1に示す。
表1に示すように、シクロホスファミド1mg負荷では、本発明のスプレー法が比較例の薄膜法より高い分解率を示した。スプレー法では噴霧条件によると思われる数値の変動を認めたものの、触媒量が増える、あるいはシクロホスファミドが減るに従い分解率が向上する傾向を認めた。今回、測定機器の定量限界の問題で、シクロホスファミドの負荷量を、キャビネット内シクロホスファミド残留量として報告されている0.1〜6.6ng/cm2(J. Vandenbroucke, H. Robays, How to protect environment and employees against cytotoxic agents, the UZ Ghent experience, J. Oncol. Pharm. Pract, 6, 146-152 (2001))、の15,000〜400,000倍と高いものにせざるを得なかったが、実際の飛散状況では、表1に示す分解率よりも高い分解率を達成できるものと考えられる。また、本実施例では、ステンレス板を、安全キャビネット内の作業平面上に水平に配置したが、実施例の組成物を垂直の壁に噴霧しても、液垂れは無かった。 As shown in Table 1, with a 1 mg load of cyclophosphamide, the spray method of the present invention showed a higher decomposition rate than the thin film method of the comparative example. In the spray method, although the fluctuation of the numerical value considered to be due to the spraying condition was recognized, the tendency of the decomposition rate to improve as the amount of the catalyst increased or the amount of cyclophosphamide decreased was recognized. This time, due to the problem of the limit of quantification of measuring instruments, the loading amount of cyclophosphamide is reported as 0.1 to 6.6 ng / cm 2 (J. Vandenbroucke, H. Robays, How to protect environment and employees against cytotoxic agents, the UZ Ghent experience, J. Oncol. Pharm. Pract, 6, 146-152 (2001)), but had to be 15,000-400,000 times higher. In the scattering state, it is considered that a higher decomposition rate than that shown in Table 1 can be achieved. Further, in this example, the stainless steel plate was disposed horizontally on the work plane in the safety cabinet, but there was no dripping even when the composition of the example was sprayed on a vertical wall.
本発明の光触媒水性組成物は、既に抗がん剤で汚染されている安全キャビネットにも噴霧するだけで使用することができ、抗がん剤を除去するのに大変有用である。 The photocatalytic aqueous composition of the present invention can be used by simply spraying it on a safety cabinet that is already contaminated with an anticancer agent, and is very useful for removing the anticancer agent.
Claims (6)
0.3〜0.5重量%の界面活性剤、
を含む、抗がん剤分解除去用の光触媒水性組成物であって、該抗がん剤を取扱う医療用安全キャビネット内壁及び作業面に噴霧して使用されることを特徴とする光触媒水性組成物。 0.1-1.0 wt% photocatalytically active titanium dioxide particles, and 0.3-0.5 wt% surfactant,
The including, a photocatalyst aqueous composition for anti-cancer agents decompose and remove, the photocatalyst aqueous composition characterized in that it is used by spraying the medical safety cabinet interior and the work surface handling anticancer agents object.
噴霧された光触媒水性組成物を乾燥する工程、及び
医療用安全キャビネット内壁及び作業面に、315〜380nmの光を10〜15時間照射する工程、
を含む、医療用安全キャビネット内壁及び作業面に付着した抗がん剤を分解除去する方法。 Spraying the photocatalytic aqueous composition according to any one of claims 1 to 4 on the inner wall and the work surface of a medical safety cabinet;
A step of drying the sprayed aqueous photocatalyst composition, and a step of irradiating a medical safety cabinet inner wall and work surface with light of 315 to 380 nm for 10 to 15 hours,
A method for decomposing and removing an anticancer agent adhering to the inner wall and work surface of a medical safety cabinet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010240664A JP5613900B2 (en) | 2010-10-27 | 2010-10-27 | Aqueous photocatalytic composition and anticancer agent decomposition method using the composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010240664A JP5613900B2 (en) | 2010-10-27 | 2010-10-27 | Aqueous photocatalytic composition and anticancer agent decomposition method using the composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012091114A JP2012091114A (en) | 2012-05-17 |
JP5613900B2 true JP5613900B2 (en) | 2014-10-29 |
Family
ID=46385096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010240664A Active JP5613900B2 (en) | 2010-10-27 | 2010-10-27 | Aqueous photocatalytic composition and anticancer agent decomposition method using the composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5613900B2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5779236B2 (en) * | 2011-04-11 | 2015-09-16 | Msドリーム株式会社 | Wipe set and wiping method using the same |
BR112015023475B1 (en) | 2013-03-15 | 2020-12-15 | Cargill, Incorporated | METHOD TO RECOVER A ENRICHED COMPOSITION IN 3-HYDROXYPROPYONIC ACID |
WO2014208428A1 (en) | 2013-06-25 | 2014-12-31 | 株式会社タムラテコ | Anticancer agent decomposition method and anticancer agent decomposition device |
KR101487758B1 (en) * | 2014-11-04 | 2015-01-30 | 김혁중 | Composition of Photocatalitic Coating Solution and Method of Preparing the Same |
JP6696838B2 (en) * | 2016-06-16 | 2020-05-20 | 株式会社フジコー | Interior material and manufacturing method thereof |
WO2019073996A1 (en) * | 2017-10-13 | 2019-04-18 | 株式会社タムラテコ | Method for treating harmful substance and ozone generator |
US11059769B2 (en) | 2017-10-26 | 2021-07-13 | Noroo Ic Co., Ltd. | Production and separation of 3-hydroxypropionic acid |
WO2021095696A1 (en) * | 2019-11-11 | 2021-05-20 | プログレス株式会社 | Method for preventing exposure to anticancer agent |
WO2021230192A1 (en) * | 2020-05-11 | 2021-11-18 | ウシオ電機株式会社 | Method for decomposing anti-cancer agent |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3458948B2 (en) * | 1999-07-01 | 2003-10-20 | 博 河合 | Composition for spraying plant foliage and method of using the same |
JP3772658B2 (en) * | 2000-09-13 | 2006-05-10 | 東陶機器株式会社 | Photocatalytic coating composition |
JP4038200B2 (en) * | 2003-07-30 | 2008-01-23 | 諭 吉村 | Manufacturing method of coating agent and coating method using the coating agent |
JP5411574B2 (en) * | 2008-05-26 | 2014-02-12 | 旭化成ケミカルズ株式会社 | Composite, functional structure and coating agent |
JP5481717B2 (en) * | 2008-12-15 | 2014-04-23 | ライオン株式会社 | Liquid photobleachable composition for textile products |
-
2010
- 2010-10-27 JP JP2010240664A patent/JP5613900B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2012091114A (en) | 2012-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5613900B2 (en) | Aqueous photocatalytic composition and anticancer agent decomposition method using the composition | |
Zhang et al. | Potent antibacterial activities of Ag/TiO2 nanocomposite powders synthesized by a one-pot sol− gel method | |
Zhang et al. | Interfacial engineering of bimetallic Ag/Pt nanoparticles on reduced graphene oxide matrix for enhanced antimicrobial activity | |
US20230157299A1 (en) | Dispensable nanoparticle based composition for disinfection | |
JP5995100B2 (en) | Disinfectant, its material, its product and method of use | |
Müller et al. | Poly (hexamethylene biguanide) adsorption on hydrogen peroxide treated Ti–Al–V alloys and effects on wettability, antimicrobial efficacy, and cytotoxicity | |
EA013401B1 (en) | Antimicrobial activity of biologically stabilized silver nano particles | |
CA2777024C (en) | Sprayable gel wound dressing | |
Torres et al. | Innovative high-surface-area CuO pretreated cotton effective in bacterial inactivation under visible light | |
US9617040B1 (en) | Disinfectant material comprising copper iodide | |
Kreeft et al. | Review of techniques to achieve optical surface cleanliness and their potential application to surgical endoscopes | |
EP2726557B1 (en) | Surface treatment agent with high photocatalytic and sanitary effects | |
JPH08165208A (en) | Antimicrobial, mildewproofing and deodorizing spraying agent | |
JP7550394B2 (en) | Medications to prevent infection | |
JP2014227369A (en) | Whole amount-jetting type aerosol product | |
US11439980B2 (en) | Contaminant-activated photocatalysis | |
CA3152759A1 (en) | Graphene-silver nanocomposites and uses for same as an antimicrobial composition | |
JP2013181102A (en) | Pollen allergen deactivator | |
JP2020174900A (en) | Medicine and method for decomposing anticancer agent | |
JP5968964B2 (en) | Method for surface treatment of articles with antibacterial and / or antiviral agents | |
Suran et al. | Tunable Release of Ions from Graphene Oxide Laminates for Sustained Antibacterial Activity in a Biomimetic Environment | |
CA2902728A1 (en) | System and method for hazardous drug surface cleaning | |
JP6152596B2 (en) | Manufacturing method of coated material and coated material | |
US11274271B2 (en) | Method and system for hazardous drug surface cleaning | |
JP2015189707A (en) | Cosmetic skin pack clay sheet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131204 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140630 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140805 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140818 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5613900 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |